RUNX3 and juvenile Huntington disease: Pathway analysis for the 38 SCGs showed significant enrichment in 11 pathways (B-H p < 0.05); Guanosine Nucleotides Degradation III, Purine Nucleotides Degradation II (Aerobic), Nucleotide catabolism, Urate Biosynthesis/Inosine 5’-phosphate Degradation, Adenosine Nucleotides Degradation II (GDA, NT5M, XDH); BAG2 Signaling Pathway, Transcriptional regulation by RUNX3 (PSMB2, PSMD3, TP53); Mitotic Metaphase and Anaphase, Cell Cycle Checkpoints, RHO GTPases activate IQGAPs (CLIP1, LMNA, PSMB2, PSMD3, TP53, IQGAP3); and Huntington’s Disease Signaling (ITPR1, PSMB2, PSMD3, TP53).